IE 11 is not supported. For an optimal experience visit our site on another browser.

Trius to Present at JMP Securities Research Conference

SAN DIEGO, May 10, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide a corporate presentation on Wednesday, May 11 at 11:30 a.m. at the Tenth Annual JMP Securities Research Conference. The presentation will take place in San Francisco, California at the Ritz Carlton in Salon II.
/ Source: GlobeNewswire

SAN DIEGO, May 10, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide a corporate presentation on Wednesday, May 11 at 11:30 a.m. at the Tenth Annual JMP Securities Research Conference. The presentation will take place in San Francisco, California at the Ritz Carlton in Salon II.

About Trius Therapeutics

Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. The company's lead product candidate, torezolid phosphate, is an IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of acute bacterial skin and skin structure infections (ABSSSI), the first such trial to be initiated under a Special Protocol Assessment (SPA). In addition to the company's torezolid phosphate clinical program, it is currently conducting three preclinical programs using its proprietary discovery platform to develop antibiotics to treat infections caused by gram-negative bacteria. For more information, visit .

CONTACT: Public Relations Contact: Jason Spark at Canale Communications, Inc. jason@canalecomm.com 619-849-6005 Investor Relations Contact: Stefan Loren at Westwicke Partners, LLC sloren@westwicke.com 443-213-0507